<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422224</url>
  </required_header>
  <id_info>
    <org_study_id>ALL-T-COPIES</org_study_id>
    <nct_id>NCT03422224</nct_id>
  </id_info>
  <brief_title>ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation</brief_title>
  <acronym>ALL-T-COPIES</acronym>
  <official_title>Alloreactive t Cell Repertoire in Kidney Transplantation Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will establish a workflow to generate unique patterns of the&#xD;
      donor-reactive T cell repertoire using mixed lymphocyte reactions to select alloreactive T&#xD;
      cell clones prior to transplantation Tissue infiltrating as well as blood bound T cells will&#xD;
      be characterized based on:&#xD;
&#xD;
        1. Identification of donor-specific T cell receptor sequences pre- and post-transplant by&#xD;
           in vitro expansion to determine unique patterns&#xD;
&#xD;
        2. Quantification and comparison of donor-specific T cell clones in kidney biopsy and blood&#xD;
           samples.&#xD;
&#xD;
        3. Analysis of the TCR repertoire diversities derived from kidney biopsy and blood samples&#xD;
           and association of repertoire diversities with the histomorphological phenotype of T&#xD;
           cell mediated rejection.&#xD;
&#xD;
        4. Identification of T cell subtypes within the donor-reactive population. The&#xD;
           investigators specifically hypothesize that highly expanded donor-reactive T cell clones&#xD;
           in both kidney tissue and blood samples at time of indication biopsy are associated with&#xD;
           the histological phenotype of acute T cell mediated rejection. The investigators have&#xD;
           previously shown that there is a strong correlation between highly expanded&#xD;
           tissue-resident T cell clones and the repertoire found in periphery blood samples. To&#xD;
           trace and quantify donor reactive T cells the investigators will apply a truly&#xD;
           quantitative approach for immune repertoire profiling based on high- throughput&#xD;
           sequencing. The investigators ultimate goal is to develop a diagnostic tool to assess&#xD;
           alloreactive cellular immunoresponses based on peripheral blood samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kidney transplant recipients receiving a non lymphodepletional induction therapy at the&#xD;
      investigators center will be included in this study.&#xD;
&#xD;
      Alloreactive T cells are defined prior to transplantation via a mixed lymphocyte reaction of&#xD;
      donor and recipient PBMC's.&#xD;
&#xD;
      Following transplantation PBMC's will be sampled at management (3 and 12 months) and&#xD;
      for-cause biopsies and fifteen patients with histological proven acute T cell mediated&#xD;
      rejection will be compared to 15 patients without histopathological signs of alloimmune&#xD;
      response in time matched for-cause biopsies.&#xD;
&#xD;
      T cell receptor beta chains of T cells found in the circulation and the allograft biopsy will&#xD;
      be sequenced via Next generation sequencing.&#xD;
&#xD;
      Abundance of alloreactive T cells of the overall repertoire pre-and post-transplant and their&#xD;
      presence in the allograft will be assessed.&#xD;
&#xD;
      The diversity of the overall repertoire and alloreactive repertoire will be compared between&#xD;
      these two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rejection</measure>
    <time_frame>12 months</time_frame>
    <description>biopsy proven rejection</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Renal Transplant Rejection</condition>
  <condition>Immune Repertoire</condition>
  <condition>Transplant; Complication, Rejection</condition>
  <condition>Alloreactivity</condition>
  <arm_group>
    <arm_group_label>Good transplant function</arm_group_label>
    <description>Kidney transplant recipients without histological signs of rejection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transplant Rejection</arm_group_label>
    <description>Kidney transplant recipinets experiencing a T cell mediated rejection episode.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Mixed lymphocyte reaction</intervention_name>
    <description>Assessment of alloreactive T cell repertoire</description>
    <arm_group_label>Good transplant function</arm_group_label>
    <arm_group_label>Transplant Rejection</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PBMC needle biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic kidney disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kidney transplantation in our center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Donor not evaluated by our center&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Oberbauer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Constantin N Aschauer, MD</last_name>
    <phone>00434040043890</phone>
    <email>constantin.aschauer@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical university of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constantin N Aschauer, MD</last_name>
      <phone>00434040043890</phone>
      <email>constantin.aschauer@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rainer Oberbauer</investigator_full_name>
    <investigator_title>Prof. Dr</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

